FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms

The continuing heavy toll of the COVID-19 pandemic necessitates development of therapeutic options. We adopted structure-based drug repurposing to screen FDA-approved drugs for inhibitory effects against main protease enzyme (Mpro) substrate-binding pocket of SARS-CoV-2 for non-covalent and covalent...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Mahmoud S., Farag, Ayman B., Boys, Ian N., Wang, Ping, Menendez-Montes, Ivan, Nguyen, Ngoc Uyen Nhi, Eitson, Jennifer L., Ohlson, Maikke B., Fan, Wenchun, McDougal, Matthew B., Mar, Katrina, Thet, Suwannee, Ortiz, Francisco, Kim, Soo Young, Solmonson, Ashley, Williams, Noelle S., Lemoff, Andrew, DeBerardinis, Ralph J., Schoggins, John W., Sadek, Hesham A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Masson SAS. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043961/
https://www.ncbi.nlm.nih.gov/pubmed/37068330
http://dx.doi.org/10.1016/j.biopha.2023.114614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043961/
https://www.ncbi.nlm.nih.gov/pubmed/37068330
http://dx.doi.org/10.1016/j.biopha.2023.114614

Ejemplares similares